China Health : Inside Information of the latest business development of China Health

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA HEALTH GROUP INC.

中 國 醫 療 集 團 有 限 公 司

(Carrying on business in Hong Kong as "萬全醫療集團") (Incorporated in the Cayman Islands with limited liability)

(Stock Code: 08225)

Inside Information of

the latest business development of China Health Group

Alzheimer's disease is the most prevalent diseases in the future and one of the seven leading causes of human death. September 21, 2021 is the 28th World Alzheimer's Disease Day and the Xi'en Prevention and Treatment Day. On this special day, the Group's Clinical Research Center for prevention and treatment of dementia and stroke launched the Real World Study with top medical institutions in China on anti-dementia clinical 10,000 patients ("The Real World Study").

The Study is aimed at improving the standardized treatment of Alzheimer's disease through clinical research by linking hundreds of grassroots hospitals with Internet technology, and involving many tertiary hospitals in China such as the Sixth Hospital of Peking University, the First Hospital of Peking University, and the General Hospital of the People's Liberation Army. The two Studies launched this time are led by Prof. Wang Huali and Prof. Mao Zhiqi respectively, with a total of 10,000 cases planned to be completed within 2 years.

Alzheimer's Disease International (ADI) said that a new report found that an estimated 41 million dementia cases worldwide have not been diagnosed and that new treatment breakthroughs could lead to an impending "Demand Tsunami" for diagnoses that could crush unprepared health care systems around the world and more than 100 global Alzheimer's disease and dementia associations worldwide.

The Management believes that the Group's Clinical Research Center for prevention and treatment of dementia and stroke has participated in the 70% of recent market clinical research of drugs in the field of dementia in China. This clinical research and the promotion of new clinical research drugs under big data will have an important impact

on the long-term revenue of the Group.

China Health Group Inc. is a leading enterprise that, driven by the three cores of the Real World Study, Real World Data and Artificial Intelligence, provides three major services for life sciences, precision digital medical "research-based specialty" CHGmyD services, Real World Study CHGRWS services and the Scientific research product promotion service of reconstructing the trillion dollar drug promotion market CRSO services. The Group focuses on the two century epidemic diseases of brain science and allergy, and constructs five specialty brands: baimin Kangmin, Xixin spirit, Xien prevention and treatment of stroke mania, Yuejie smoking addiction and ALS.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company and, in case of doubt, to seek independent advice from professionals or financial advisers.

By order of the Board

China Health Group Inc.

GUO Xia

Chairman

Hong Kong, 23 September 2021

As at the date hereof, the Board comprises two executive Directors, being Mr. GUO Xia and Dr. SONG Xuemei; one non- executive Director, being Mr. SU Yi; and three independent non-executive Directors, being Mr. QIU Rui, Dr. NI Binhui and Mr. ZHEN Ling.This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading. This announcement will remain on the "Latest Listed Company Information" page of the GEM website at http://www.hkgem.com for 7 days from the date of its posting. This announcement will also be posted on the Company's website at http://www.chgi.net.